To establish the recommended Phase II dose of a flavored preparation of orally administered irinotecan (VAL-413) when given in combination with temozolomide for 5 consecutive days.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Patrick Thompson
Pediatrics - Hematology/Oncology
Clinical or Medical
Interventional
Cancer (Pediatric Cancers, Sarcoma (bone and soft tissue), Phase 1 Trials (all cancers))
22-2142